Similar Items: Association of the PD‐L1 CPS With the Efficacy of First‐Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer
- First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
- Biomarker‐based long‐term safety and efficacy of PD‐1/PD‐L1 inhibitors combined with chemotherapy in advanced gastroesophageal carcinomas: A systematic review and meta‐analysis
- Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non‐Squamous Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study
- Gemcitabine-Based versus Fluoropyrimidine-Based Chemotherapy and Role of Platinum Combination for First-Line Palliative Systemic Treatment in Advanced Ampullary Adenocarcinoma
- Venetoclax Plus Blinatumoma as First Line Therapy for Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia
- Prognostic Impact of the Systemic Immune-Inflammation Index in Unresectable Hepatocellular Carcinoma Undergoing Second-Line Combination Therapy: A Multicenter Study